Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 T Cells After Haploidentical HSCT in Hematologic Malignancies
NCT01744223Phase 2Active, not recruiting
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Mar 2013
- Primary completion
- Oct 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rivogenlecleucel in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoma, myelodysplastic syndrome (MDS), sponsored by Bellicum Pharmaceuticals, Inc.. Started Mar 2013; status: active, not recruiting.
02
Drugs
rivogenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)lymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01744223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01744223.